vitiligo

Incyte reports positive data from Phase III vitiligo trial
Clinical Trials Arena
Thu, 10/12/23 - 05:27 pm
Incyte
Opzelura
vitiligo
clinical trials
Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Endpoints
Tue, 03/21/23 - 10:06 am
AAD
Incyte
JAK inhibitors
povorcitinib
vitiligo
Incyte reports data from Phase IIb vitiligo therapy trial
Clinical Trials Arena
Mon, 03/20/23 - 11:27 am
Incyte
povorcitinib
vitiligo
clinical trials
Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech
Endpoints
Mon, 10/3/22 - 10:21 am
Incyte
M&A
Villaris Therapeutics
vitiligo
Medicxi
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
BioSpace
Mon, 07/18/22 - 10:22 am
FDA
Incyte
Arcutis Biotherapeutics
Opzelura
vitiligo
roflumilast
psoriasis
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Fierce Pharma
Mon, 03/14/22 - 11:37 pm
Incyte
Opzelura
eczema
vitiligo
FDA sets April date for verdict on Incyte’s vitiligo drug
Pharmaforum
Wed, 12/15/21 - 10:43 am
Incyte
Opzelura
vitiligo
FDA
Incyte’s Ruxolitinib Cream Shows Promise for Vitiligo in Phase III Trials Published: May 17, 2021 By Brandon May
BioSpace
Mon, 05/17/21 - 11:02 pm
Incyte
ruxolitinib
vitiligo
clinical trials
Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo
Pharmaceutical Business Review
Thu, 09/26/19 - 07:42 pm
Incyte
clinical trials
ruxolitinib
vitiligo